Article Information
History
- March 7, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Spyros Chalkias, M.D.1,*,
- Howard Schwartz, M.D.2,
- Biliana Nestorova, M.B.A.1,
- Jing Feng, M.S.1,
- Ying Chang, M.S.1,
- Honghong Zhou, Ph.D.1,
- Frank J. Dutko, Ph.D.1,
- Darin K. Edwards, Ph.D.1,
- David Montefiori, Ph.D.3,
- Rolando Pajon, Ph.D.1,
- Brett Leav, M.D.1,
- Jacqueline M. Miller, M.D.1 and
- Rituparna Das, M.D.1
- 1Moderna, Inc., Cambridge, Massachusetts, USA
- 2CMO Research Centers of America, Hollywood, Florida, USA
- 3Department of Surgery and Duke Human Vaccine Institute, Durham, North Carolina, USA
- ↵*Corresponding Author: Spyros Chalkias M.D., Spyros.Chalkias{at}modernatx.com, (617) 335 0744, Moderna, Inc., 200 Technology Square, Cambridge, Massachusetts 02139
Posted March 07, 2022.
Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
